The Collaborative Center for Translational Mass Spectrometry (CCTMS) at TGen and The integrated Mass Spectrometry and Proteomics Facility (MSPCF) at the City of Hope, supervised by Dr. Patrick Pirrotte, provide end-to-end solutions tailored for translational and clinical research.
We employ highly sensitive mass spectrometry approaches to perform ultra-deep proteomics profiling (i.e., >90% of the expressed proteome) in tissues and tumors. We provide quantification of proteins, metabolites and lipids with unbeatable precision and depth. Assays are tailored towards clinical proteomics needs, such as FFPE proteomics or biomarker discovery in biofluids (e.g., plasma, serum, urine, saliva). Approaches for metaproteomic and metabolic profiling of microbial pathogens and microbiomes in longitudinal clinical samples have been established.
In addition, the Center has developed unique approaches that enable comprehensive and functional characterization of protein phosphorylation and kinome discovery to map key signaling pathways in support of the development of novel targeted therapies. Its bioinformatics pipeline provides data integration across proteomics, metabolomics, genomics and transcriptomics to provide a united and actionable overview of tumor biology in precision medicine clinical trials.
Our technologies also enable unbiased biomarker discovery approaches and targeted biomarker validation, thereby supporting the translation of basic science into applied clinical research.
Contact Information
Patrick Pirrotte, Ph.D. Assistant Professor, Cancer and Cell Biology Division Director, Collaborative Center for Translational Mass Spectrometry
445 N. Fifth Street
[email protected]
602-343-8454
With a combined 50+years of collaborative experience with leading academic, biotech, pharma and industry partners, we deliver innovative and customized services in mass spectrometry based biotechnologies, including development and optimization for highly multiplexed protein discovery and quantification
Disease and Systems Biology Applications
The CCTMS employs highly sensitive mass spectrometry approaches to perform ultra-deep proteomics profiling (i.e., >90% of the expressed proteome) in tissues and tumors. Assays are tailored towards clinical proteomics needs, such as FFPE proteomics or biomarker discovery in biofluids (e.g., plasma, serum, urine, saliva). Approaches for metaproteomic and metabolic profiling of microbial pathogens and microbiomes in longitudinal clinical samples have been established.
In addition, the Center has developed unique approaches that enable comprehensive and functional characterization of protein phosphorylation and kinome discovery to map key signaling pathways in support of the development of novel targeted therapies. Its bioinformatics pipeline provides data integration across proteomics, metabolomics, genomics and transcriptomics to provide a united and actionable overview of tumor biology in precision medicine clinical trials.